Meeting
2024 ASCO Annual Meeting
Combined EORTC FDG-PET/CT and RECIST 1.1 response criteria and prediction of pathological response to neoadjuvant nivolumab and ipilimumab for clinical stage III melanoma.
Authors
Milton Jose De Barros E Silva
A.C. Camargo Cancer Center, São Paulo, Brazil
Milton Jose De Barros E Silva , Monique Celeste Tavares , Joao Paulo S. N. Lima , Daniel Garcia , Jose Augusto Rinck Jr , Andre Molina , Matheus Lobo , Clovis Antonio Lopes Pinto , Rafaela Brito De Paula , Alexander Christopher Jonathan van Akkooi , João Pedreira Duprat Neto
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Local-Regional Disease
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 9590)
DOI
10.1200/JCO.2024.42.16_suppl.9590
Abstract #
9590
Poster Bd #
374
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
FDG-PET/CT response and prediction of pathological response to neoadjuvant nivolumab and ipilimumab for clinical stage III melanoma.
First Author: Milton Jose De Barros E Silva
Poster
2022 ASCO Annual Meeting
The interferon-gamma (IFN-y) signature from baseline tumor material predicts pathologic response after neoadjuvant ipilimumab (IPI) + nivolumab (NIVO) in stage III melanoma.
First Author: Irene L.M. Reijers
Poster
2022 ASCO Annual Meeting
Survival update of neoadjuvant ipilimumab + nivolumab in macroscopic stage III melanoma: The OpACIN and OpACIN-neo trials.
First Author: Judith M. Versluis
Poster
2020 ASCO Virtual Scientific Program
Twenty-four months RFS and updated toxicity data from OpACIN-neo: A study to identify the optimal dosing schedule of neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in stage III melanoma.
First Author: Elisa A. Rozeman